Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G.S. Nowakowski

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY

Hematological Oncology

English

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Pet-Cr as a Surrogate for Survival Outcomes in Dlbcl: A Literature Based Meta-Analysis

Hematological Oncology

English

Persistent Mediastinal Positron Emission Tomography (Pet)-Positivity After Frontline Therapy for Hodgkin Lymphoma Is Best Managed by Close Observation

Hematological Oncology

English

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Beyond Maximum Grade: A Novel, Longitudinal Toxicity Over Time (Toxt) Adverse Event Analysis of Lenalidomide in Follicular Lymphoma in Calgb 50401 (Alliance)

Hematological Oncology

English

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

Hematological Oncology

English

Addition of Lenalidomide to R-Chop (R2chop) Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl): First Report of Ecog-Acrin1412 a Randomized Phase 2 Us Intergroup Study of R2chop vs R-Chop

Hematological Oncology

English

Clinical Features, Treatment and Outcome of Neurolymphomatosis: Single Institution Experience

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G.S. Nowakowski

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Pet-Cr as a Surrogate for Survival Outcomes in Dlbcl: A Literature Based Meta-Analysis

Persistent Mediastinal Positron Emission Tomography (Pet)-Positivity After Frontline Therapy for Hodgkin Lymphoma Is Best Managed by Close Observation

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Beyond Maximum Grade: A Novel, Longitudinal Toxicity Over Time (Toxt) Adverse Event Analysis of Lenalidomide in Follicular Lymphoma in Calgb 50401 (Alliance)

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

Addition of Lenalidomide to R-Chop (R2chop) Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl): First Report of Ecog-Acrin1412 a Randomized Phase 2 Us Intergroup Study of R2chop vs R-Chop

Clinical Features, Treatment and Outcome of Neurolymphomatosis: Single Institution Experience